Clinical trial
Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate Safety and Effectiveness of Hypoxic RBCs Processed With the Hemanext ONE System vs Conventional RBCs in Patients With Transfusion-Dependent Haematological Malignancies
NCT06685848 is registered in ClinicalTrials.gov with Hemanext as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate Safety and Effectiveness of Hypoxic RBCs Processed With the Hemanext ONE System vs Conventional RBCs in Patients With Transfusion-Dependent Haematological Malignancies
- Lead sponsor
- Hemanext
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- November 29, 2024
- Completion date
- August 31, 2028
- Enrollment
- 24 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.